Arvinas ARVN

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.24 (+1.33%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Business overview of Arvinas (ARVN)
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.

Key Insights

Critical company metrics and information

  • Latest Closing Price

    $18.28

  • Market Cap

    $1.26 Billion

  • Price-Earnings Ratio

    -3.82

  • Total Outstanding Shares

    68.77 Million Shares

  • Total Employees

    430

  • Dividend

    No dividend

  • IPO Date

    September 27, 2018

  • SIC Description

    Pharmaceutical Preparations

  • Primary Exchange

    NASDAQ

  • Type

    Common Stock

  • Headquarters

    395 winchester ave, New haven, CT, 06511

  • Homepage

    https://www.arvinas.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Financing Activities$342.20 Million
Net Cash Flow$-34 Million
Net Cash Flow, Continuing$-34 Million
Net Cash Flow From Operating Activities$-258.30 Million
Net Cash Flow From Financing Activities, Continuing$342.20 Million
Net Cash Flow From Investing Activities, Continuing$-117.90 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Preferred Stock Dividends And Other Adjustments$0
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0
Net Income/Loss Available To Common Stockholders, Basic$-308.60 Million
Net Income/Loss$-308.60 Million
Other Operating Expenses$153.60 Million
Benefits Costs and Expenses$467.10 Million

Comprehensive Income

October 1, 2023 to September 30, 2024
MetricValue
Other Comprehensive Income/Loss$-295.30 Million
Comprehensive Income/Loss Attributable To Parent$-295.30 Million
Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
Comprehensive Income/Loss$-295.30 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Fixed Assets$6.80 Million
Other Non-current Liabilities$304.40 Million
Noncurrent Assets$17.60 Million
Equity Attributable To Parent$586 Million
Equity$586 Million
Accounts Payable$17.70 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Recent Headlines From The Web

Latest news, press releases, and media coverage about ARVN from trusted financial sources
    All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

    ⓒ 2025 Financhle. All Rights Reserved.